Biodexa Pharmaceuticals (BDRX) Short Interest Ratio & Short Volume $1.46 -0.03 (-2.01%) As of 04/30/2025 03:59 PM Eastern Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock Biodexa Pharmaceuticals Short Interest DataBiodexa Pharmaceuticals (BDRX) has a short interest of 290,200 shares, representing 0.80% of the float (the number of shares available for trading by the public). This marks a 323.65% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.2, indicating that it would take 0.2 days of the average trading volume of 583,431 shares to cover all short positions.Current Short Interest290,200 sharesPrevious Short Interest68,500 sharesChange Vs. Previous Month+323.65%Dollar Volume Sold Short$423,692.00Short Interest Ratio0.2 Days to CoverLast Record DateApril 15, 2025Outstanding Shares36,544,000 sharesShort Percent of Float0.80%Today's Trading Volume15,801 sharesAverage Trading Volume583,431 sharesToday's Volume Vs. Average3% Short Selling Biodexa Pharmaceuticals? Sign up to receive the latest short interest report for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartBDRX Short Interest Over TimeBDRX Days to Cover Over TimeBDRX Percentage of Float Shorted Over Time Biodexa Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/2025290,200 shares $423,692.00 +323.7%0.8%0.2 $1.46 3/31/202568,500 shares $90,420.00 +10.3%0.2%0 $1.32 3/15/202562,100 shares $117,990.00 +72.0%0.2%0 $1.90 2/28/202536,100 shares $120,213.00 -23.2%0.1%0 $3.33 2/15/202547,000 shares $200,690.00 +1,368.8%0.1%0.1 $4.27 1/31/20253,200 shares $14,112.00 -50.8%N/A0 $4.41 1/15/20256,500 shares $27,787.50 -37.5%N/A0 $4.28 12/31/202410,400 shares $42,120.00 -62.6%N/A0 $4.05 12/15/202427,800 shares $116,760.00 -46.5%N/A0.1 $4.20 11/30/202452,000 shares $292,240.00 +225.0%N/A0.2 $5.62 Get the Latest News and Ratings for BDRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/15/202416,000 shares $57,920.00 +15.9%N/A0.1 $3.62 10/31/202413,800 shares $84,870.00 -50.2%N/A0.1 $6.15 10/15/202427,700 shares $138,777.00 +108.3%N/A0.2 $5.01 9/30/202413,300 shares $3,753.26 -83.7%N/A0.2 $0.28 9/15/202481,400 shares $33,536.80 -5.2%N/A0.1 $0.41 8/31/202485,900 shares $47,245.00 -17.7%N/A0.1 $0.55 8/15/2024104,400 shares $63,130.68 +63.4%N/A0.1 $0.60 7/31/202463,900 shares $44,091.00 -89.2%N/A0 $0.69 7/15/2024589,700 shares $572,009.00 +318.5%N/A0.1 $0.97 6/30/2024140,900 shares $126,232.31 -35.6%N/A0 $0.90 6/15/2024218,800 shares $214,642.80 -34.6%N/A0 $0.98 5/31/2024334,700 shares $322,784.68 +3.9%N/A0.1 $0.96 5/15/2024322,000 shares $363,860.00 -84.4%N/A0.1 $1.13 4/30/20242,060,000 shares $3.11 million +986.5%N/A0.6 $1.51 4/15/2024189,600 shares $157,974.72 +183.8%N/A0.1 $0.83 3/31/202466,800 shares $108,216.00 -34.9%N/A0 $1.62 3/15/2024102,600 shares $120,042.00 -32.3%N/A0.2 $1.17 2/29/2024151,600 shares $192,532.00 -37.1%N/A0.3 $1.27 2/15/2024241,100 shares $383,349.00 +414.1%N/A0.2 $1.59 1/31/202446,900 shares $75,509.00 +3.3%N/A0.1 $1.61 1/15/202445,400 shares $91,254.00 -46.7%N/A0.1 $2.01 12/31/202385,100 shares $228,068.00 -51.8%N/A0.1 $2.68 12/15/2023176,500 shares $524,205.00 -43.3%N/A0.3 $2.97 11/30/2023311,300 shares $1.13 million +3,044.4%N/A0.5 $3.62 11/15/20239,900 shares $25,344.00 -5.7%N/A0 $2.56 10/31/202310,500 shares $39,690.00 -61.5%N/A0 $3.78 10/15/202327,300 shares $132,132.00 +875.0%N/A0.1 $4.84 9/30/20232,800 shares $13,972.00 -63.6%N/A0 $4.99 9/15/20237,700 shares $47,586.00 -64.2%N/A0 $6.18 8/31/202321,500 shares $171,785.00 -28.3%N/A0 $7.99Virtually Limitless Energy? (Ad)A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.One company’s discovery could change power forever 8/15/202330,000 shares $148,800.00 -50.3%N/A0.1 $4.96 7/31/202360,300 shares $328,635.00 -27.1%N/A0.1 $5.45 7/15/202382,700 shares $445,753.00 +100.2%N/A0.3 $5.39 6/30/202341,300 shares $226,654.40 -85.5%N/A0.3 $5.49 6/15/2023284,600 shares $22,141.88 +156.2%N/A0.1 $0.08 5/31/2023111,100 shares $9,332.40 -37.8%N/A0 $0.08 5/15/2023178,700 shares $40,475.55 No ChangeN/A0.1 $0.23 3/15/202384,900 shares $118,860.00 +41.7%N/A1.6 $1.40 2/28/202359,900 shares $31,148.00 +0.5%N/A1.2 $0.52 2/15/202359,600 shares $37,548.00 +111.4%N/A1.3 $0.63 1/31/202328,200 shares $19,742.82 +18.0%N/A0.7 $0.70 1/15/202323,900 shares $15,535.00 -38.2%N/A0.8 $0.65 12/30/202238,700 shares $38,119.50 +26.9%N/A2 $0.99 12/15/202230,500 shares $24,403.05 +254.7%N/A1.7 $0.80 11/30/20228,600 shares $13,674.00 -1.2%N/A0.4 $1.59 11/15/20228,700 shares $13,892.16 +6.1%N/A0.4 $1.60 10/31/20228,200 shares $15,908.00 +310.0%N/A0.3 $1.94 10/15/20222,000 shares $3,848.60 -39.4%N/A0.1 $1.92 9/30/20223,300 shares $6,138.00 -61.6%N/A0.1 $1.86 9/15/20228,600 shares $28,638.00 -74.2%N/A0.4 $3.33 8/31/202233,300 shares $24,642.00 +69.0%N/A0.7 $0.74 8/15/202219,700 shares $14,676.50 -63.3%N/A0.1 $0.75 7/31/202253,700 shares $35,168.13 +47.9%N/A0.3 $0.65 7/15/202236,300 shares $26,136.00 -44.8%N/A0.2 $0.72 6/30/202265,800 shares $35,532.00 -24.2%N/A0.3 $0.54 6/15/202286,800 shares $44,935.49 +617.4%N/A0.4 $0.52 5/31/202212,100 shares $7,578.46 -28.8%N/A0.1 $0.63 5/15/202217,000 shares $8,924.98 +794.7%N/A0.3 $0.52 4/30/20221,900 shares $1,235.00 -93.7%N/A0 $0.65 4/15/202230,100 shares $25,886.00 -28.8%N/A0.5 $0.86 3/31/202242,300 shares $37,224.00 +6.0%N/A0.7 $0.88 3/15/202239,900 shares $32,953.37 +17.0%N/A0.5 $0.83 2/28/202234,100 shares $33,452.10 -55.3%N/A0.3 $0.98 2/15/202276,300 shares $76,071.10 +149.4%N/A0.6 $1.00 1/31/202230,600 shares $30,906.00 -42.8%N/A0.2 $1.01 1/15/202253,500 shares $60,455.00 +59.7%N/A0.4 $1.13 12/31/202133,500 shares $35,175.00 -83.7%N/A0.2 $1.05 12/15/2021205,800 shares $234,612.00 +53.5%N/A1.6 $1.14 11/30/2021134,100 shares $195,786.00 +9.2%N/A1.4 $1.46 11/15/2021122,800 shares $200,164.00 -31.3%N/A1.2 $1.63 10/29/2021178,700 shares $303,790.00 +19.1%N/A1.8 $1.70 10/15/2021150,000 shares $255,750.00 +1.6%N/A1.4 $1.71 9/30/2021147,600 shares $256,824.00 -12.4%N/A1.2 $1.74 9/15/2021168,500 shares $291,505.00 +1.9%N/A1.1 $1.73 8/31/2021165,400 shares $302,682.00 -34.0%N/A0.1 $1.83 8/13/2021250,600 shares $455,315.14 -9.4%N/A0.1 $1.82 7/30/2021276,700 shares $514,662.00 +0.8%N/A0.1 $1.86 7/15/2021274,600 shares $503,891.00 -18.0%N/A0.1 $1.84 6/30/2021334,700 shares $696,176.00 +102.2%N/A0.2 $2.08 6/15/2021165,500 shares $331,000.00 No ChangeN/A0.1 $2.00Virtually Limitless Energy? (Ad)A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.One company’s discovery could change power forever 5/28/2021165,500 shares $316,105.00 -7.9%N/A0.7 $1.91 5/14/2021179,700 shares $359,400.00 +10.5%N/A0.6 $2.00 4/30/2021162,600 shares $320,322.00 +7.4%N/A0.4 $1.97 4/15/2021151,400 shares $307,342.00 -15.7%N/A0.2 $2.03 3/31/2021179,500 shares $384,130.00 +7.1%N/A0.2 $2.14 3/15/2021167,600 shares $398,888.00 -13.8%N/A0.2 $2.38 2/26/2021194,400 shares $480,168.00 -5.6%N/A0.2 $2.47 2/12/2021206,000 shares $585,040.00 +89.3%N/A0.2 $2.84 1/29/2021108,800 shares $233,920.00 +1.2%N/A0.1 $2.15 1/15/2021107,500 shares $245,100.00 -36.1%N/A0.3 $2.28 12/31/2020168,200 shares $319,580.00 +43.5%N/A0.4 $1.90 12/15/2020117,200 shares $227,496.92 +2.5%N/A0.3 $1.94 11/30/2020114,400 shares $208,208.00 -16.3%N/A0.3 $1.82 11/15/2020136,600 shares $260,906.00 -12.1%N/A0.4 $1.91 10/30/2020155,400 shares $289,044.00 +50.0%N/A0 $1.86 10/15/2020103,600 shares $198,912.00 -3.6%N/A0 $1.92 9/30/2020107,500 shares $194,575.00 -7.7%N/A0 $1.81 9/15/2020116,500 shares $228,340.00 -48.7%N/A0 $1.96 8/31/2020227,100 shares $526,872.00 +4,731.9%N/A0 $2.32 8/14/20204,700 shares $12,784.00 -99.6%N/A0 $2.72 7/31/20201,120,000 shares $2.28 million +5,585.3%N/A0.3 $2.04 7/15/202019,700 shares $25,413.00 +146.3%N/A0 $1.29 6/30/20208,000 shares $11,120.00 -73.6%N/A0 $1.39 6/15/202030,300 shares $42,117.00 +83.6%N/A0.1 $1.39 5/29/202016,500 shares $22,935.00 +96.4%N/A0.1 $1.39 5/15/20208,400 shares $23,184.00 +13.5%N/A0.1 $2.76 BDRX Short Interest - Frequently Asked Questions What is Biodexa Pharmaceuticals' current short interest? Short interest is the volume of Biodexa Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 290,200 shares of BDRX short. 0.80% of Biodexa Pharmaceuticals' shares are currently sold short. Learn More on Biodexa Pharmaceuticals' current short interest. What is a good short interest percentage for Biodexa Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.80% of Biodexa Pharmaceuticals' floating shares are currently sold short. Is Biodexa Pharmaceuticals' short interest increasing or decreasing? Biodexa Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 290,200 shares, an increase of 323.6% from the previous total of 68,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Biodexa Pharmaceuticals' short interest compare to its competitors? 0.80% of Biodexa Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Biodexa Pharmaceuticals: Acelyrin, Inc. (5.04%), SOPHiA GENETICS SA (0.09%), Neurogene Inc. (24.36%), CARGO Therapeutics, Inc. (18.87%), Amarin Co. plc (3.05%), Annexon, Inc. (9.29%), Ocugen, Inc. (24.63%), iTeos Therapeutics, Inc. (6.12%), Y-mAbs Therapeutics, Inc. (8.91%), Gossamer Bio, Inc. (4.26%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Biodexa Pharmaceuticals stock? Short selling BDRX is an investing strategy that aims to generate trading profit from Biodexa Pharmaceuticals as its price is falling. BDRX shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Biodexa Pharmaceuticals? A short squeeze for Biodexa Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BDRX, which in turn drives the price of the stock up even further. How often is Biodexa Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BDRX, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies Acelyrin Short Interest Data SOPHiA GENETICS Short Interest Data Neurogene Short Interest Data CARGO Therapeutics Short Interest Data Amarin Short Interest Data Annexon Short Interest Data Ocugen Short Interest Data iTeos Therapeutics Short Interest Data Y-mAbs Therapeutics Short Interest Data Gossamer Bio Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BDRX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
